Biotech
-
Janux impresses Wall Street with new prostate cancer drug results
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to…
Read More » -
Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and…
Read More » -
How Intra-Cellular surprised Wall Street by breaking character
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue forecast for its schizophrenia…
Read More » -
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed…
Read More » -
New data could help Merck expand use of cardiovascular drug
Positive results from a study of Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent expirations…
Read More » -
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although…
Read More » -
Biotech startups are built on venture capital. Track funding rounds here.
Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into…
Read More » -
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a…
Read More » -
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with…
Read More » -
‘Find any advantage’: 3 biotech leaders on driving R&D success
“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel…
Read More »